FDA grants Pediatric Disease Designation for Mateon’s OT101
Mateon Therapeutics announced the FDA granted Rare Pediatric Disease Designation for OT101/Trabedersen for treatment of diffuse intrinsic pontine glioma as a drug for a “rare pediatric disease.” DIPG, is an orphan disease with a low survival rate and no established or effective standard of care. September 23, 2019